Journey Medical Corporation to Participate in the 37th Annual ROTH Conference
Journey Medical (Nasdaq: DERM), a commercial-stage pharmaceutical company focused on marketing FDA-approved dermatological prescription products, has announced its participation in the 37th Annual ROTH Conference from March 16-18, 2025, in Dana Point, California.
President and CEO Claude Maraoui will lead a fireside chat on Tuesday, March 18 at 12:30 p.m. PT and will be available for one-on-one meetings throughout the conference. Investors can access the fireside chat webcast on Journey Medical's website investor section for approximately 30 days following the event.
Journey Medical (Nasdaq: DERM), un'azienda farmaceutica in fase commerciale focalizzata sulla commercializzazione di prodotti dermatologici da prescrizione approvati dalla FDA, ha annunciato la sua partecipazione al 37° Annual ROTH Conference che si terrà dal 16 al 18 marzo 2025 a Dana Point, California.
Il Presidente e CEO Claude Maraoui condurrà una chiacchierata informale martedì 18 marzo alle 12:30 PT e sarà disponibile per incontri individuali durante tutta la conferenza. Gli investitori possono accedere alla diretta della chiacchierata sul sito web di Journey Medical nella sezione dedicata agli investitori per circa 30 giorni dopo l'evento.
Journey Medical (Nasdaq: DERM), una empresa farmacéutica en etapa comercial centrada en la comercialización de productos dermatológicos de prescripción aprobados por la FDA, ha anunciado su participación en la 37ª Conferencia Anual ROTH que se llevará a cabo del 16 al 18 de marzo de 2025 en Dana Point, California.
El Presidente y CEO Claude Maraoui liderará una charla informal el martes 18 de marzo a las 12:30 p.m. PT y estará disponible para reuniones individuales durante toda la conferencia. Los inversores pueden acceder a la transmisión en vivo de la charla en el sitio web de Journey Medical en la sección para inversores durante aproximadamente 30 días después del evento.
Journey Medical (Nasdaq: DERM), FDA 승인 피부과 처방 제품의 마케팅에 중점을 둔 상업 단계 제약 회사가 2025년 3월 16일부터 18일까지 캘리포니아 다나 포인트에서 열리는 제37회 연례 ROTH 컨퍼런스에 참가한다고 발표했습니다.
회장 겸 CEO Claude Maraoui가 3월 18일 화요일 오후 12:30 PT에 화상 대화를 주도하며, 컨퍼런스 기간 동안 일대일 회의도 가능합니다. 투자자들은 이벤트 이후 약 30일 동안 Journey Medical 웹사이트의 투자자 섹션에서 화상 대화 웹캐스트에 접근할 수 있습니다.
Journey Medical (Nasdaq: DERM), une entreprise pharmaceutique en phase commerciale axée sur la commercialisation de produits dermatologiques sur ordonnance approuvés par la FDA, a annoncé sa participation à la 37e Conférence Annuelle ROTH qui se tiendra du 16 au 18 mars 2025 à Dana Point, Californie.
Le Président et CEO Claude Maraoui animera une discussion informelle le mardi 18 mars à 12h30 PT et sera disponible pour des réunions individuelles tout au long de la conférence. Les investisseurs peuvent accéder à la diffusion en direct de la discussion sur le site Web de Journey Medical dans la section investisseurs pendant environ 30 jours après l'événement.
Journey Medical (Nasdaq: DERM), ein kommerziell tätiges Pharmaunternehmen, das sich auf die Vermarktung von von der FDA zugelassenen dermatologischen verschreibungspflichtigen Produkten konzentriert, hat seine Teilnahme an der 37. jährlichen ROTH-Konferenz vom 16. bis 18. März 2025 in Dana Point, Kalifornien, bekannt gegeben.
Präsident und CEO Claude Maraoui wird am Dienstag, den 18. März um 12:30 Uhr PT ein informelles Gespräch leiten und steht während der gesamten Konferenz für persönliche Treffen zur Verfügung. Investoren können die Übertragung des Gesprächs auf der Investorenseite der Website von Journey Medical etwa 30 Tage nach der Veranstaltung abrufen.
- None.
- None.
SCOTTSDALE, Ariz., March 12, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that management will participate in the 37th Annual ROTH Conference, which is being held March 16-18, 2025 in Dana Point, California.
Claude Maraoui, President and Chief Executive Officer, will participate in a fireside chat on Tuesday, March 18 at 12:30 p.m. PT and will be available for one-on-one meetings throughout the conference.
A webcast of the company’s fireside chat will be available on the News and Events page of the Investors section of Journey Medical’s website, www.journeymedicalcorp.com, for approximately 30 days after the meeting.
About Journey Medical Corporation
Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical”) is a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions through its efficient sales and marketing model. The Company currently markets seven branded and two generic products that help treat and heal common skin conditions. The Journey Medical team comprises industry experts with extensive experience in developing and commercializing some of dermatology’s most successful prescription brands. Journey Medical is located in Scottsdale, Arizona and was founded by Fortress Biotech, Inc. (Nasdaq: FBIO). Journey Medical’s common stock is registered under the Securities Exchange Act of 1934, as amended, and it files periodic reports with the U.S. Securities and Exchange Commission (“SEC”). For additional information about Journey Medical, visit www.journeymedicalcorp.com.
Company Contact:
Jaclyn Jaffe
Journey Medical Corporation
(781) 652-4500
ir@jmcderm.com
Media Relations Contact:
Tony Plohoros
6 Degrees
(908) 591-2839
tplohoros@6degreespr.com
FAQ
When is Journey Medical (DERM) presenting at the ROTH Conference 2025?
How can investors watch Journey Medical's (DERM) ROTH Conference presentation?
What type of meetings will Journey Medical (DERM) conduct at the ROTH Conference 2025?
Who will represent Journey Medical (DERM) at the 2025 ROTH Conference?
